Inactive Instrument

Can Fite Biopharma Ltd Stock TEL AVIV STOCK EXCHANGE

Equities

IL0010944739

Pharmaceuticals

Sales 2024 * 800K 303M Sales 2025 * 800K 303M Capitalization 10.26M 3.88B
Net income 2024 * -6M -2.27B Net income 2025 * -7M -2.65B EV / Sales 2024 * 12.8 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 12.8 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.97%
More Fundamentals * Assessed data
Dynamic Chart
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study CI
Can-Fite Biopharma Ltd. Announces Clinical Update CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson CI
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon MT
Top Midday Gainers MT
Can-Fite Biopharma Reports 'Complete Response' in Liver Cancer Patient Treated With Namodenoson MT
More news
Managers TitleAgeSince
Chief Executive Officer 59 03-07-31
Founder 74 94-09-10
Founder 67 94-09-10
Members of the board TitleAgeSince
Director/Board Member 76 00-12-31
Founder 67 94-09-10
Founder 74 94-09-10
More insiders
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Calendar
More about the company